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The newly emerging human pathogen influenza A
H7N9 represents a potentially major threat to human
health. The virus was first shown to be pathogenic in
humans in 2013, and outbreaks continue to occur in
China to the present time. The current incident
mortality rate is disturbingly high despite the frequent
use of antiviral therapy and intensive care management.
If the virus gains the capacity for efficient person-to-
person transmission, a global influenza pandemic could
ensue with devastating consequences. In the absence
of an effective vaccine, targeted regulation of the host
immune response by immune modulators might be
considered. Readily available, approved drugs with
immune-modulating activities might prove to be a
treatment option in combination with existing antiviral
agents and supportive care.On the day of admission, the investigators performedIn this issue of Critical Care Wu and colleagues provide
a tantalizing glimpse into the immune dysfunction and
possible immunopathogenesis of infection due to the
novel H7N9 avian strain of influenza A virus [1]. Human
cases of H7N9 influenza have thus far occurred only in
China and surrounding regions [2-4], but there is dis-
turbing evidence that this virus could easily evolve and
create a pandemic of immense proportions. The ob-
served case fatality rate in H7N9 influenza is much
higher (about 25%) than that seen in patients infected
with pandemic H1N1 virus in 2009 [5,6]. The H7N9
virus is derived from an avian influenza A virus that has
crossed species barriers to infect humans, primarily
those who have had exposure to live poultry markets.
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2014human-to-human transmission probably occurs, al-
though there is no evidence of continued spread thus far
[2,3]. The virus causes essentially asymptomatic infec-
tion in chickens, but when transmitted to humans it
leads to a highly symptomatic and potentially lethal ill-
ness. Severe H7N9 illness affects predominantly older
patients (mean age ≥60 years), unlike pandemic H1N1
or avian influenza A H5H1 virus infections that affect
younger individuals [1].
Wu and colleagues studied 27 H7N9 patients who were
hospitalized at one center in Zhejiang Province in China
and compared their immune responses with 30 healthy
controls. All of the patients were severely ill (mean Acute
Physiology and Chronic Health Evaluation II score 22)
and all were treated with oseltamivir. Diffuse lymphopenia
was seen in two-thirds of patients. More than 70% of pa-
tients developed acute respiratory distress syndrome and
almost 50% acquired secondary bacterial pneumonia.
multiplex cytokine analyses and flow cytometry to survey
circulating peripheral blood mononuclear cells for activa-
tion or markers of T-cell anergy or exhaustion. Compared
with healthy controls, cytokine analyses revealed elevated
IL-6, IL-8 and IL-10 levels, but no increase in tumor ne-
crosis factor, gamma-interferon or other proinflammatory
cytokines. Flow cytometry showed increases in CD38, a
marker of T-cell activation, and T-cell immunoglobulin
and mucin protein-3 (TIM3), a surface marker for T-cell
anergy/exhaustion. Conversely, human leukocyte antigen
DR expression and TIM3-expressing monocytes were sig-
nificantly lower. TIM3 is a well-characterized indicator of
T-cell exhaustion in the mice, but this may not be true in
humans [7]. Regrettably, the investigators did not measure
programmed cell death-1 on T cells, which is a reliable
marker of lymphocyte exhaustion in both mice and
humans [1]. They were also unable to perform serial de-
terminations of inflammatory markers to document the
course of immune dysfunction over time.ntral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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enza differ substantially from those seen in younger pa-
tients infected by the pandemic H1N1 influenza virus or
the more pathogenic avian influenza A H5N1 viruses [1].
H5N1 patients often have significant elevations of tumor
necrosis factor and gamma-interferon, neither of which
was seen with H7N9 influenza. Instead, a mixed pattern of
proinflammatory (IL-6 and IL-8) and anti-inflammatory
(IL-10) cytokines was observed, along with simultaneous
expressions of T-cell activation (CD38) and de-activation
(TIM3). These differences might reflect the unique viru-
lence properties of the H7N9 virus or differences in the
host response of older H7N9 patients.
A major question is whether patients with severe
H7N9 influenza could benefit from immune modulator
therapy in addition to antiviral agents and supportive
care [8,9]. Many fundamental questions need to be an-
swered. It is unclear whether the immune profile de-
scribed by Wu and colleagues is a manifestation of the
host response to the virus or whether immune dysregu-
lation is actually contributing to the pathogenesis of the
disease. Could the immune response be specifically tar-
geted to aid patient recovery? Optimal treatment may
not simply be a question of giving proinflammatory or
anti-inflammatory agents. It may depend upon patient
age, the specific virus, the presence of co-morbid illness,
the extent of disease and the timing of the intervention
[10-12].Table 1 Low-cost, readily available drugs with immunomodul
influenza
Drug class Proposed mechanism of prot
influenza
HMG CoA reductase inhibitors (statins);
lipid-lowering agents with numerous anti-
inflammatory and vasoprotective effects
Alter prenylation pattern of enz
membranes: vaso-protection; lo
reduce oxidative stress; upregu
upregulate AMPK and PGC-1 al
oxidase activity
Aspirin, a cyclooxygenase inhibitor, might
potentiate statin effects
Unknown, may shunt oxygenat
to lipooxygenase pathway; mig
actions
PPAR-gamma agonists (thiazolidinediones,
glitazones); anti-diabetic treatments with
effects on mitochondrial biogenesis
Agonist for PGC-1 alpha that pr
mitochondrial function and bio
apoptosis
PPAR-alpha agonists (fibrates); lipid-
lowering agents with effects on mitochon-
drial biogenesis
Promotes mitochondrial functio
Angiotension II inhibitors – ARB agents and
ACE inhibitors
Blocks angiotensin II ligation to
superoxide generation by NAD
AMPK agonists (metformin), anti-diabetic
agents with immune-metabolic effects
AMPK reduces oxidant stress an
apoptotic signals
Resveratrol, a polyphenol nutritional
supplement
Stimulates sirtuin activity, activa
PGC-1 alpha, protects against o
ACE, angiotensin-converting enzyme; AMPK, adenosine monophosphate protein kin
eNOS, endogenous endothelial nitric oxide synthase; HMG CoA, 3-hydroxy-3-methy
hydrogen; PGC-1 alpha, peroxisome proliferator activated receptor gamma coactiva
like receptor.Several commonly prescribed therapeutic agents that
have immunomodulatory effects have been shown to be
effective in treating influenza in experimental settings
and in observational studies of patients with pneumonia
and influenza (and even one randomized controlled trial
in sepsis; Table 1) [9,13]. Statins are the agents best
studied, but several other drug classes might also have
clinical utility [13,14]. Many of these drugs are produced
as inexpensive generics and are widely distributed in
low-income and middle-income countries [9,13].
Randomized controlled trials will be needed to deter-
mine whether adjuvant therapies will benefit patients
with severe influenza. These studies should be con-
ducted during outbreaks of seasonal influenza. We con-
cur with health officials in the USA that it is morally
imperative to perform such investigations before and
during pandemics in order to guide clinicians respon-
sible for managing patients with severe influenza [15].
Undertaking such trials during pandemics will take cour-
age and coordination, but failure to act in an organized
fashion will condemn patients to haphazard and unregu-
lated efforts by clinicians desperate to find something
that might benefit their patients. In the 21st century it is
unacceptable to remain uninformed and ill prepared in
inter-pandemic periods when we know that it is simply a
matter of time before the next influenza pandemic oc-
curs. The study by Wu and colleagues should prompt an
international effort to better characterize the hostatory activities that could benefit patients with severe





Animal studies; numerous observational studies in
pneumonia and one in human influenza; one
randomized, controlled trial in human sepsis
ed lipid precursors
ht amplify statin




Animal studies with influenza virus challenge
models




Human observational studies in pneumonia
patients, no data on influenza patients thus far
d induces anti- Preclinical studies, no data in influenza patients
thus far
tes PPAR alpha and
xidant stress
Improved survival in animal studies with influenza
challenge models
ase; ARB, angiotensin receptor blocker; AT-1, angiotensin II type 1 receptor;
lglutaryl coenzyme A; NADPH, nicotinamide adenine dinucleotide phosphate
tor-1 alpha; PPAR, peroxisome proliferator activated receptor; TLR, toll
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clinical trials that will define successful strategies for
treatment.
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